Want to see SE:FLUI full AI Analyst Report?
FLUI Stock Chart & Stats
kr10.00
>-kr0.01(-1.38%)
At close: 4:00 PM EST
kr10.00
>-kr0.01(-1.38%)
Day’s Range― - ―
52-Week Rangekr7.65 - kr67.20
Previous CloseN/A
Volume175.18K
Average Volume (3M)16.23K
Market Cap
kr41.49M
Enterprise Valuekr13.95
Total Cash (Recent Filing)kr1.30M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding1,373,703
10 Day Avg. Volume8,193
30 Day Avg. Volume16,225
Financial Highlights & Ratios
PEG Ratio1.01
Price to Book (P/B)74.56
Price to Sales (P/S)135.42
P/FCF Ratio-59.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr68.60M
Bulls Say, Bears Say
Bulls Say
Niche Single-cell Microfluidics PlatformFluicell's core product set targets single-cell biology and cell-based research, a durable niche with growing demand from drug discovery, disease modeling and advanced therapies. Specialized tools create higher technical barriers to entry and persistent demand from research and industrial labs.
Sharp TTM Revenue Rebound With Positive Gross ProfitA near-doubling in trailing revenue and a positive gross profit indicate the company is beginning to convert product development into repeatable sales. Sustained top-line growth and positive gross margins are foundational for scaling operations and driving long-term margin improvement if maintained.
Conservative Balance Sheet With No DebtZero debt and positive equity lower refinancing and interest risks, giving management flexibility to fund commercialization or R&D through equity or grants. This conservative position supports survival through cash burn phases and strategic investments without immediate solvency pressure.
Bears Say
Persistent Negative Operating And Free Cash FlowOngoing negative operating and free cash flows demonstrate continued cash burn and limited self-financing capacity. Over months, this raises dependence on external capital, increases dilution or financing risk, and constrains the firm's ability to invest consistently in sales, manufacturing scale-up, or product expansion.
Ongoing Unprofitability And Deeply Negative MarginsDespite revenue gains, persistent operating and net losses indicate the cost structure is not yet aligned with revenues. Deep negative margins hinder return generation, require structural cost or pricing changes to achieve sustainable profitability, and limit long-term investor confidence if unresolved.
Very Small Scale And Historical VolatilityA tiny workforce and prior volatility in gross profit signal limited operational scale and execution capacity. Small size increases reliance on a few projects or customers, raises operational risk during growth, and can slow commercial expansion needed to transform strong R&D into consistent revenues.
FLUI FAQ
What was Fluicell AB’s price range in the past 12 months?
Fluicell AB lowest stock price was kr7.65 and its highest was kr67.20 in the past 12 months.
What is Fluicell AB’s market cap?
Fluicell AB’s market cap is kr41.49M.
When is Fluicell AB’s upcoming earnings report date?
Fluicell AB’s upcoming earnings report date is Aug 21, 2026 which is in 20 days.
How were Fluicell AB’s earnings last quarter?
Fluicell AB released its earnings results on May 08, 2026. The company reported kr2.409 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fluicell AB overvalued?
According to Wall Street analysts Fluicell AB’s price is currently Overvalued.
Does Fluicell AB pay dividends?
Fluicell AB does not currently pay dividends.
What is Fluicell AB’s EPS estimate?
Fluicell AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fluicell AB have?
Fluicell AB has 1,373,703 shares outstanding.
What happened to Fluicell AB’s price movement after its last earnings report?
Fluicell AB reported an EPS of kr2.409 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 48.444%.
Which hedge fund is a major shareholder of Fluicell AB?
Currently, no hedge funds are holding shares in SE:FLUI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fluicell AB
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.